Back to News
Market Impact: 0.35
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Source: 247wallst.com
Healthcare & BiotechMarket Technicals & Flows
A late-stage melanoma vaccine report was posted online and quickly pulled, prompting what the article describes as a violent repricing in Moderna shares. The report’s findings appeared favorable, but the excerpt gives no direction or magnitude for the share move; Moderna stock is quoted at $184.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Why Moderna stock plunged despite positive cancer vaccine trail results?
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports